AstraZeneca to pay $425M to settle Nexium, Prilosec litigation
Wirestock
AstraZeneca (NASDAQ:AZN) said it has agreed to pay $425M to settle substantially all of the product liability litigation filed against the company over its anti-acid medications Nexium and Prilosec.
The British drugmaker said in a statement filed with the SEC that it still believes the claims are âwithout meritâ and has admitted no wrongdoing as part of the settlements, adding that the agreements allow it to avoid âcostlyâ litigation.
AstraZeneca said terms of the settlements were confidential. It added that a single liability case remains, filed in a US district court in the state of Louisiana. A trial for that case is scheduled to begin on April 15.
Shares of AstraZeneca were trading relatively flat in early trading Tuesday. 

More on AstraZeneca

AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths
AstraZeneca: Robust Performance And Promising Growth Initiatives
AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)
Merck, Bristol Myers, AstraZeneca agree to Medicare drug pricing talks
AstraZeneca upgraded to buy at Jefferies on assets beyond oncology